Diagnosing cervical cancer and high-grade precursors by HPV16 transcription patterns

Cancer Research

Volumn 70, Issue 1, 2010, Pages 249-256

  Schmitt, Markus ^a   Dalstein, Véronique ^b   Waterboer, Tim ^a   Clavel, Christine ^b   Gissmann, Lutz ^a   Pawlita, Michael ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b REIMS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; PROTEIN E6; PROTEIN E7; TRANSCRIPTOME; VIRUS DNA;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER SCREENING; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC VALUE; DISEASE SEVERITY; DOWN REGULATION; FEMALE; GENE AMPLIFICATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RNA ANALYSIS; SQUAMOUS CELL CARCINOMA; UPREGULATION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU;

CROSS-SECTIONAL STUDIES; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN PAPILLOMAVIRUS 16; HUMANS; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; RNA, VIRAL; TRANSCRIPTION, GENETIC; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 75149186947     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-2514     Document Type: Article

References (31)

1. Munoz N, Bosch FX, de Sanjose SE. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
2. Durst M, Gissmann L, Ikenberg H, zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci U S A 1983;80:3812-5.
3. Schwarz E, Freese UK, Gissmann L, et al. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 1985;314:111-4.
4. Munger K, Phelps WC, Bubb V, Howley PM, Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 1989;63:4417-21.
5. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533-43.
6. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 2004 Incidence and Mortality. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2007.
7. Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993;12:186-92.
8. Baldwin P, Laskey R, Coleman N. Translational approaches to improving cervical screening. Nat Rev 2003;3:217-26.
9. Stoler MH. HPV for cervical cancer screening: is the era of the molecular pap smear upon us? J Histochem Cytochem 2001;49:1197-8.
10. Fahey MT, Irwig L, Macaskill P. Meta-analysis of Pap test accuracy. Am J Epidemiol 1995;141:680-9.
11. Wright TCJR, Schiffman M, Solomon D, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol 2004;103:304-9.
12. Molden T, Kraus I, Karlsen F, Skomedal H, Nygard JF, Hagmar B. Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. Cancer Epidemiol Biomarkers Prev 2005;14:367-72.
13. Castle PE, Dockter J, Giachetti C, et al. A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical precancer and cancer. Clin Cancer Res 2007;13:2599-605.
14. Cuschieri KS, Whitley MJ, Cubie HA. Human papillomavirus type specific DNA and RNA persistence-implications for cervical disease progression and monitoring. J Med Virol 2004;73:65-70.
15. Molden T, Kraus I, Karlsen F, Skomedal H, Hagmar B. Human papillomavirus E6/E7 mRNA expression in women younger than 30 years of age. Gynecol Oncol 2006;100:95-100.
16. Clavel C, Cucherousset J, Lorenzato M, et al. Negative human papillomavirus testing in normal smears selects a population at low risk for developing high-grade cervical lesions. Br J Cancer 2004;90:1803-8.
17. Clavel C, Masure M, Bory JP, et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 2001;84:1616-23.
18. Schmitt M, Bravo IG, Snijders PJ, Gissmann L, Pawlita M, Waterboer T. Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol 2006;44:504-12.
19. Schmitt M, Dondog B, Waterboer T, Pawlita M. Homogeneous amplification of genital human α papillomaviruses by PCR using novel broad-spectrum GP5+ and GP6+ primers. J Clin Microbiol 2008;46: 1050-9.
20. Zheng ZM, Baker CC. Papillomavirus genome structure, expression, and post-transcriptional regulation. Front Biosci 2006;11: 2286-302.
21. Compton J. Nucleic acid sequence-based amplification. Nature 1991;350:91-2.
22. Smits HL, van Gemen B, Schukkink R, et al. Application of the NASBA nucleic acid amplification method for the detection of human papillomavirus type 16 E6-7 transcripts. J Virol Methods 1995;54: 75-81.
23. Kraus I, Molden T, Erno LE, Skomedal H, Karlsen F, Hagmar B. Human papillomavirus oncogenic expression in the dysplastic portio; an investigation of biopsies from 190 cervical cones. Br J Cancer 2004; 90:1407-13.
24. Greijer AE, Dekkers CA, Middeldorp JM. Human cytomegalovirus virions differentially incorporate viral and host cell RNA during the assembly process. J Virol 2000;74:9078-82.
25. Larkin MA, Blackshields G, Brown NP, et al. Clustal W and Clustal X version 2.0. Bioinformatics 2007;23:2947-8.
26. Deiman B, van Aarle P, Sillekens P. Characteristics and applications of nucleic acid sequence-based amplification (NASBA). Mol Biotechnol 2002;20:163-79.
27. Sherman L, Alloul N, Golan I, Durst M, Baram A. Expression and splicing patterns of human papillomavirus type-16 mRNAs in pre-cancerous lesions and carcinomas of the cervix, in human keratinocytes immortalized by HPV 16, and in cell lines established from cervical cancers. Int J Cancer 1992;50:356-64.
28. Alloul N, Sherman L. The E2 protein of human papillomavirus type 16 is translated from a variety of differentially spliced polycistronic mRNAs. J Gen Virol 1999;80:29-37.
29. Alloul N, Sherman L. Transcription-modulatory activities of differentially spliced cDNAs encoding the E2 protein of human papillomavirus type 16. J General Virol 1999;80:2461-70.
30. Vinokurova S, Wentzensen N, Kraus I, et al. Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res 2008;68:307-13.
31. Middleton K, Peh W, Southern S, et al. Organization of human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers. J Virol 2003;77: 10186-201.